BIOCHEMICAL PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
BIOCHEMICAL PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
批准号:
3163111
负责人:
ALAN CLAYTON SARTORELLI
金额:
$27.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1978
资助国家:
美国
项目状态:
已结题
起止时间:
1978-01-01 至 1993-12-31
关键词:
annexins anthracyclines antineoplastics basosquamous cell carcinoma biological signal transduction cell differentiation clone cells cytoskeleton daunorubicin disease /disorder model doxorubicin drug adverse effect drug design /synthesis /production drug metabolism eicosanoids enzyme inhibitors epidermal growth factor erythroleukemia erythropoietin fluorescent dye /probe gene expression glucocorticoids granulocyte laboratory mouse leukemia microtubules monocyte neoplasm /cancer chemotherapy neoplasm /cancer pharmacology neoplastic cell oncogenes phospholipase A2 phospholipase inhibitor tissue /cell culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (adapted from the applicant's abstract): The objectives of the
proposed research are to develop therapeutic drug regimens that will have
use in the treatment of cancer in man on the basis of pharmacological and
biochemical information on the mechanism of drug action, and fundamental
information in processes in neoplastic cells that may be considered
cellular sites of vulnerability. To accomplish these objectives, this
application will use the induction of terminal differentiation of
neoplastic cells by chemical and/or biological agents as a therapeutic
approach to the treatment of cancer. To achieve these goals the specific
aims are: (a) to characterize the role of the lipocortins and eicosanoids
in the maturation of squamous carcinoma and leukemia cells; (b) to
determine cytosketal changes during the transition from the immature cell
to the mature state; (c) to study the mechanism of induction of leukemia
cell differentiation by anthracyclines; (d) to develop and employ in vivo
systems to determine the therapeutic effectiveness of differentiation
inducing agents; (e) to evaluate the role of fos and jun oncogenes in
leukemia cell maturation; and (f) to study the mechanism of signal
transduction by erythropoietin in erythroleukemia cells. It is anticipated
that information will be obtained which will provide significant leads that
will ultimately result in the development of approaches with clinical
utility that function to produce therapeutic benefit in cancer patients by
the induction of the terminal differentiation of neoplastic cells, as well
as provide information on factors involved in the regulation of malignant
cell growth and differentiation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TUMOR SELECTIVE INACTIVATION OF THE REPAIR PROTEIN AGT
-
批准号:8518508
-
项目类别:
-
资助金额:$0.69万
-
财政年份:2011
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
TUMOR SELECTIVE INACTIVATION OF THE REPAIR PROTEIN AGT
-
批准号:7318303
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2007
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
Hypoxia-Activated O6-Benzylguanine Prodrugs
-
批准号:7247982
-
项目类别:
-
资助金额:$28.52万
-
财政年份:2006
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
Hypoxia-Activated O6-Benzylguanine Prodrugs
-
批准号:8080493
-
项目类别:
-
资助金额:$28.5万
-
财政年份:2006
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
Hypoxia-Activated O6-Benzylguanine Prodrugs
-
批准号:7433889
-
项目类别:
-
资助金额:$28.52万
-
财政年份:2006
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
Development of Anticancer 1,2-Bis(sulfonyl)hydrazines
-
批准号:7475212
-
项目类别:
-
资助金额:$29.46万
-
财政年份:2006
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
Hypoxia-Activated O6-Benzylguanine Prodrugs
-
批准号:8243689
-
项目类别:
-
资助金额:$28.5万
-
财政年份:2006
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
Development of Anticancer 1,2-Bis(sulfonyl)hydrazines
-
批准号:7667764
-
项目类别:
-
资助金额:$29.54万
-
财政年份:2006
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
Hypoxia-Activated O6-Benzylguanine Prodrugs
-
批准号:7129307
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2006
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
Hypoxia-Activated O6-Benzylguanine Prodrugs
-
批准号:7985227
-
项目类别:
-
资助金额:$29.38万
-
财政年份:2006
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
Development of Anticancer 1,2-Bis(sulfonyl)hydrazines
-
批准号:7101262
-
项目类别:
-
资助金额:$30.33万
-
财政年份:2006
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
Development of Anticancer 1,2-Bis(sulfonyl)hydrazines
-
批准号:7264547
-
项目类别:
-
资助金额:$29.45万
-
财政年份:2006
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES
-
批准号:6869547
-
项目类别:
-
资助金额:$32.74万
-
财政年份:2002
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES
-
批准号:6711131
-
项目类别:
-
资助金额:$32.74万
-
财政年份:2002
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES
-
批准号:6434987
-
项目类别:
-
资助金额:$32.74万
-
财政年份:2002
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES
-
批准号:6621549
-
项目类别:
-
资助金额:$32.74万
-
财政年份:2002
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT
-
批准号:6370533
-
项目类别:
-
资助金额:$36.79万
-
财政年份:2001
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT
-
批准号:6750741
-
项目类别:
-
资助金额:$36.79万
-
财政年份:2001
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT
-
批准号:6920818
-
项目类别:
-
资助金额:$36.79万
-
财政年份:2001
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT
-
批准号:6638004
-
项目类别:
-
资助金额:$36.79万
-
财政年份:2001
-
负责人:ALAN CLAYTON SARTORELLI
-
依托单位:
海外基金